Genmab presents three positive Phase 3 trials supporting potential 2027 launches
GMAB•Genmab reported positive results from three Phase 3 trials, supporting potential approvals and launches beginning in 2027. EPKINLY cut progression-or-death risk by 51%, Rina-S by 71%, and petosemtamab with pembrolizumab cut death risk by 50%.
1. Trial results
Genmab said EPKINLY reduced the risk of progression or death by 51% versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. Rina-S reduced progression-or-death risk by 71% versus chemotherapy in platinum-resistant ovarian cancer, with significantly improved overall survival. Petosemtamab with pembrolizumab reduced death risk by 50% versus pembrolizumab alone in first-line recurrent or metastatic PD-L1-positive head and neck cancer.
2. Sales estimates
Genmab estimated peak sales opportunities above $3 billion for EPKINLY, above $2 billion for Rina-S, and multiple billions for petosemtamab.
